OVERVIEW

Low Dose Naltrexone (LDN) 2021 Extra Course is organized by Low Dose Naltrexone (LDN) Research Trust.

Term of Offering:
This activity is certified for credit from June 4, 2021 to June 4, 2022. Requests for credit must be made no later than September 1, 2022.

Target Audience:
MD’s, ND’s Pharmacists, NP’s, Nurses and other medical professionals wishing to learn more about Low Dose Naltrexone (LDN)

Statement of Need/Program Overview:
The LDN Research Trust partners with clinicians, clinical researchers, pharmacists, and patients to support breakthroughs in treatment for autoimmune diseases and cancer via the development of clinical trials. Now, more than ever, we must encourage life-long learning among clinicians so that they may exceed the standard of care. CME ensures the enhancement of clinicians’ performance and the pursuit of patient health.

Educational Objectives:
• Describe how LDN can impact the inflammation associated with psoriasis and psoriatic comorbidities.
• Differentiate treatment pharmacology differences between high and low doses of naltrexone.
• Discuss the role of low dose naltrexone in the treatment of Lyme disease.
• Describe the impact of microbiome on autoimmune pathology.
• List what clinical trials are presently being conducted in the field of LDN effectiveness in fibromyalgia.
• Explain how mental health disorders can complicate or undermine LDN treatment of somatic disorders.
• Discuss the theoretical physiological and biochemical effect of LDN in Erectile
• Dysfunction
• Describe the synergistic effects of LDN and testosterone
• Explain potential uses of Low Dose Naltrexone in treating HSP and its sequalae
• Discuss practical aspects of cancer therapy with LDN
• List the LDN dosing strategy for infertile patients and approach to pregnancy.